reports
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45t...
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference Daix (France), New York City (New York, United States), August 11, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that Jason Campagna, MD, PhD, President of R&D and Chief Medical Officer, and David Nikodem, PhD, Vice President of US Operations will participate in a fireside chat at the Canacc...
Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conf...
Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conference » Daix (France), New York City (New York, Etats-Unis), le 11 aout 2025 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui que Jason Campagna, MD, PhD, Président de la R&D et Directeur Médical, et David Nikodem, PhD, Vice-Président des opérations aux États-Unis, participeront à un « fireside chat » lors d...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvr...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Keple...
Bilan semestriel du contrat de liquidité de la société Inventiva concl...
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York (New York, Etats-Unis), le 31 juillet 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite non alcoolique ("NASH") et d’autres maladies avec un besoin médical non satisfait significatif, annonce aujourd’hui le bilan semestriel de son contrat de liquidité conclu avec Kepler Cheuvreux. Au titre du contrat de...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Inventiva Preliminary 1H25 cash and revenues, confirms cash runway to ...
Inventiva reported uneventful preliminary 1H25 cash and revenues with revenues of € 4.5m, and a cash position of € 122.1m and € 24.6m in short term deposits (YE24: € 96.6m), and confirmed its cash runway to the end of 3Q26. This funding should take the company to completion of the ongoing 72-week phase 3 (NATiV3) trial of lanifibranor (pan-PPAR agonist) in MASH (F2/F3), which completed recruitment in April 2025. With the funding overhang lifted, a fully recruited phase 3 trial in MASH, as well a...
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
Inventiva Reports Preliminary 2025 First-Half Financial Information¹ Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits2 as of June 30, 2025Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City (New York, United States), July 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported certain preliminary financial results for the f...
Inventiva publie ses informations financières préliminaires du premier...
Inventiva publie ses informations financières préliminaires du premier semestre 2025¹ Trésorerie et équivalents de trésorerie de 122,1 millions d’euros et 24,6 millions d’euros de dépôts à court terme2 au 30 juin 2025Chiffre d’affaires de 4,5 millions d’euros au premier semestre 2025 Daix (France), New York City (New York, Etats-Unis), le 29 juillet 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabol...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
- Wim Hoste
Inventiva names Jason Campagna as President of R&D and Chief Medical O...
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality AssuranceThese key leadership appointments underscore Inventiva’s commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half...
Inventiva annonce la nomination de Jason Campagna en tant que Présiden...
Inventiva annonce la nomination de Jason Campagna en tant que Président de la R&D et Directeur Médical et de Martine Zimmermann en tant que Vice-Présidente Exécutive en charge des affaires réglementaires et de l’assurance qualité Jason Campagna, MD, PhD, rejoint Inventiva en tant que Président de la R&D et Directeur Médical, succédant à Pierre Broqua, PhD, et Michael Cooreman, MDMartine Zimmermann, PharmD, rejoint l'entreprise en tant que Vice-Présidente Exécutive en charge des affaires réglementaires et de l’assurance qualité Ces nominations clés au sein de l’équipe de direction reflètent ...
- Jacob Mekhael
- Lynn Hautekeete
- Thomas Vranken
- Wim Hoste
- Jacob Mekhael
- Thomas Vranken
Inventiva FIRST LOOK: $ 10m milestone from CTTQ
Inventiva has received a $ 10m milestone payment from Chia Tai-Tianqing Pharma (CTTQ), under their 2022 licensing deal to develop and commercialize lanifibranor for MASH in Greater China. This payment follows the successful settlement of Inventiva's second financing tranche and aligns with expectations shared in their 1Q25 update. Together with the €68m cash position at 1Q25 and € ~109m net proceeds from the second tranche, Inventiva is expected to be funded through 3Q26. The Phase 3 NATiV3 tria...
Inventiva receives $10 million milestone payment from CTTQ
Inventiva receives $10 million milestone payment from CTTQ Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the receipt of a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (“CTTQ”), a subsidiary of Sino Biopharm. This milestone payment follows the successful settlement of the sec...
Inventiva receives $10 million milestone payment from CTTQ
Inventiva receives $10 million milestone payment from CTTQ Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the receipt of a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (“CTTQ”), a subsidiary of Sino Biopharm. This milestone payment follows the successful settlement of the sec...
Inventiva announces the publication in Journal of Hepatology Reports o...
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease Analysis of liver sinusoidal endothelial cells (“LSEC”) from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and a further increased capillarization in patients with MASH In addition, in the subgroup of patients without MASH, there was higher LSEC capillarization in patients with MASLD than thos...
Inventiva annonce la publication dans le Journal of Hepatology Reports...
Inventiva annonce la publication dans le Journal of Hepatology Reports des résultats du lanifibranor sur les cellules endothéliales sinusoïdales hépatiques chez des patients MASLD/MASH et dans des modèles précliniques de la maladie L'analyse des cellules endothéliales sinusoïdales hépatiques (« LSEC ») dans les biopsies de screening et de fin de traitement dans l'étude de Phase 2b NATIVE a mis en évidence une capillarisation des LSEC chez les patients atteints de MASLD, avec une capillarisation encore plus marquée chez les patients atteints de MASH. De plus, parmi les patients sans MASH, ...
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Bo...
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company’s Annual General Meeting. Mark Pruzanski, C...
Inventiva Annonce la Nomination de Renée Aguiar-Lucander à son Conseil...
Inventiva Annonce la Nomination de Renée Aguiar-Lucander à son Conseil d’Administration Daix (France), New York City (New York, États-Unis), le 10 juin 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui la nomination de Renée Aguiar-Lucander à son Conseil d’administration. Cette nomination a été approuvée par les actionnaires lors de récente Assemblée Générale An...
Inventiva to Participate in the Upcoming Jefferies Global Healthcare C...
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s Management will participate in two upcoming investor conferences in June 2025. Frédéric Cren, CEO and cofounder of Inventiva, will p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.